Author:
Song Qingkun,Zhou Xinna,Yu Jing,Dong Ningning,Wang Xiaoli,Yang Huabing,Ren Jun,Kim Lyerly H
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Bevers, T. B. et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. Journal of the National Comprehensive Cancer Network: JNCCN 7, 1060–1096 (2009).
2. Beslija, S. et al. Second consensus on medical treatment of metastatic breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 18, 215–225, 10.1093/annonc/mdl155 (2007).
3. Yu, J. et al. [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 43, 151–156 (2011).
4. Ekhart, C. et al. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. British journal of clinical pharmacology 67, 50–60, 10.1111/j.1365-2125.2008.03321.x (2009).
5. Lu, Z. et al. DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells. Frontiers in bioscience (Elite edition) 3, 240–249 (2011).
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献